INmune Bio Inc

NASDAQ:INMBUnited States

04:12 PM EDT, 10/31/2024 (MT Newswires) -- ...

EXPENSES General and administrative 2,219 2,586 7,369 7,223 Research and development 10,067 5,985 25,813 14,266 ---------- ---------- ---------- ---------- Total operating expenses 12,286 8,571 33,182 21,489 ---------- ---------- ---------- ---------- LOSS FROM OPERATIONS (12,286) (8,528) (33,168) (21,362) ---------- ---------- ---------- ---------- OTHER INCOME (EXPENSE), NET 193 (35) 304 (238) ---------- ---------- ---------- ---------- NET LOSS $ (12,093) $ (8,563) $ (32,864) $ (21,600) ========== ========== ========== ========== Net loss per common share -- basic and diluted $ (0.60) $ (0.48) $ (1.71) $ (1.20) Weighted average common shares outstanding -- basic and diluted 20,185,676 18,008,295 19,176,853 17,966,990 COMPREHENSIVE LOSS Net loss $ (12,093) $ (8,563) $ (32,864) $ (21,600) Other comprehensive loss -- foreign currency translation (323) (23) (237) (36) ---------- ---------- ---------- ---------- Total comprehensive loss $ (12,416) $ (8,586) $ (33,101) $ (21,636) ========== ========== ========== ========== INMUNE BIO INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) For the Nine Months Ended September 30, ----------------------------- 2024 2023 --------------- ----------- CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ (32,864) $ (21,600) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 5,848 5,489 Accretion of debt discount 73 179 Changes in operating assets and liabilities: Research and development tax credit receivable 796 6,012 Other tax receivable 226 186 Prepaid expenses 646 2,492 Prepaid expenses -- related party 127 34 Other assets 49 (30) Accounts payable and accrued liabilities 2,689 (1,531) Accounts payable and accrued liabilities -- related parties 20 70 Deferred liabilities 60 (120) Accrued liability -- long-term - 254 Operating lease liabilities (18) (14) ----------- ---------- Net cash used in operating activities (22,348) (8,579) ----------- ---------- CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from sale of common stock and warrants 27,789 775 Repayments of debt (7,500) (2,500) ----------- ---------- Net cash provided by financing activities 20,289 (1,725) ----------- ---------- Impact on cash from foreign currency translation (237) (36) NET DECREASE IN CASH AND CASH EQUIVALENTS (2,296) (10,340) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 35,848 52,153 ----------- ---------- CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 33,552 $ 41,813 =========== ========== SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: Cash paid for income taxes $ - $ - Cash paid for interest expense $ 661 $ 1,394